<DOC>
	<DOCNO>NCT02507050</DOCNO>
	<brief_summary>The aim study test whether , patient angina flow limit epicardial coronary artery disease , pre-treatment Ivabradine , oppose beta blocker , reduce post percutaneous coronary intervention induce microvascular dysfunction .</brief_summary>
	<brief_title>Ivabradine Post-revascularisation Microcirculatory Dysfunction</brief_title>
	<detailed_description>We recruit patient stable angina refer percutaneous intervention ( PCI ) due flow limit coronary artery disease . All patient exist beta blocker prescription ( standard first line angina therapy ) . Our hypothesis Ivabradine attenuate microvascular dysfunction post PCI compare standard beta-blocker pre-treatment . We intend test randomise , open-label parallel arm study direct comparison Ivabradine beta-blockers ( standard therapy ) . Patients randomise receive either Ivabradine ( stop beta blocker ) continue beta blocker 6 week prior PCI procedure . The primary endpoint IMR ( index microvascular resistance ) post PCI , marker microvascular dysfunction procedural relate myocardial injury . IMR potent marker adverse outcome STEMI patient ACS PCI . Although yet assess elective setting , reduction IMR Ivabradine may indicate potential improve outcome lessen iatrogenic microvascular dysfunction post PCI . IMR assess use thermodilution catheter place distal coronary stenosis produce hyperaemia . To assess medium term effect microcirculation post PCI patient stress perfusion cardiac MRI 12 week post procedure . The secondary endpoint proportion patient coronary flow reserve ( CFR ) &lt; 2.0 PCI territory ( regional myocardial blood flow hyperaemia intravenous adenosine infusion compare rest ) . We also assess CFI ( collateral flow index ) , promotion collateral system one method Ivabradine may lessen procedural relate myocardial injury , ΔIMR difference IMR pre post-PCI . The measurement cardiac troponins use cardiac MRI facilitate identification peri-procedural myocardial injury procedural relate myocardial infarction secondary end point . The Seattle Angina Questionnaire use 3 interval ass symptom throughout study . The total study length patient 18 week .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Symptoms Angina Pectoris 2 . Angiographic evidence epicardial coronary artery stenosis refer PCI 3 . Flow limit lesion ( Fractional Flow Reserve ≤0.80 ) one follow location ( defined SYNTAX trial89 ) : 1 . Proximal mid leave anterior descend artery ( LAD ) 2 . Proximal mid dominant right coronary artery ( RCA ) 3 . Proximal leave circumflex artery ( LCx ) 1ST Obtuse marginal Vessel 4 . Existing beta blocker prescription 5 . Echocardiogram perform within precede 12 month 6 . Patient consent 1 . Previous myocardial infarction ( MI ) target vessel myocardial territory MI precede 12 month ( defined patient history , ECG change evidence regional wall motion abnormality echocardiography ) 2 . FFR &gt; 0.80 target vessel time procedure 3 . Requirement Multivessel intervention single procedure 4 . Any chronic total occlusion ( 100 % epicardial occlusion ) angiography 5 . Distal coronary artery stenosis affect nondominant RCA 6 . Heart Rate &lt; 60 bpm inclusion ( assessed 12 lead ECG minimum 10 minute rest period ) 7 . Any rhythm sinus rhythm 8 . Sick sinus syndrome high grade atrioventricular block 9 . Permanent Pacemaker situ 10 . Congenital QT Syndrome 11 . Intolerance allergy betablockers 12 . Intolerance Ivabradine 13 . Additional ( angina pectoris ) indication betablocker treatment e.g . ventricular tachycardia 14 . Concurrent require use ratelimiting drug betablockers 15 . The necessity combination therapy Ivabradine bisoprolol achieve heart rate control 16 . Contraindication Magnetic Resonance Imaging IV adenosine 17 . Severe impairment renal function ( eGFR &lt; 30ml/min ) 18 . Severe Liver Disease ( Any bad Grade A ChildPugh Classification )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Ivabradine</keyword>
	<keyword>Microvascular dysfunction</keyword>
	<keyword>PCI</keyword>
	<keyword>Procedural relate myocardial injury</keyword>
	<keyword>IMR</keyword>
	<keyword>Index Microvascular Resistance</keyword>
</DOC>